including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic ...

“The suzetrigine Phase 2 results clearly show reduced pain intensity from baseline in the active ... autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1.

EDO51, an investigational therapy for Duchenne muscular dystrophy (DMD), and is still ongoing in the United Kingdom.

Wellington Management Group LLP decreased its position in Dyne Therapeutics, Inc. (NASDAQ:DYN – Free Report) by 81.6% in the ...

The "Myotonic Dystrophy - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The report delivers an in-depth understanding of Myotonic Dystrophy, historical and ...

The Company today announced that Dipal Doshi, Chief Executive Officer, will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 11:15 a.m. PT (2:15 p.m. ET ...

The FDA has put a stop to U.S. initiation of PepGen’s Phase II trial for its Duchene muscular dystrophy treatment. The ...

Another of PepGen’s trials has encountered resistance from the FDA, with the regulator now putting the company’s plans to ...

PepGen (PEPG) announced that the FDA has placed a clinical hold on the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in Duchenne muscular ... of what happened to PepGen when they initiated U.S. sites in ...

Zodasiran is an antisense rnai oligonucleotide commercialized by Arrowhead Pharmaceuticals, with a leading Phase II program in Familial Hypercholesterolemia (Type II Hyperlipoproteinemia).

Equities researchers at Robert W. Baird initiated coverage on shares of Dyne Therapeutics (NASDAQ:DYN – Get Free Report) in a ...

Neurofibromatosis is a genetic nervous system disorder that causes tumors to grow around nerves. There are three types of neurofibromatosis: type 1 (NF1), type 2 (NF2), and schwannomatosis. An ...